China Health Industries Holdings, Inc. engages in the production, marketing, and distribution of medicines, health products, health devices, and cosmetics. The company is headquartered in Harbin, Heilongjiang and currently employs 32 full-time employees. The company went IPO on 2004-12-01. The firm's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The firm owns a GMP-certified plant and production facilities and has the capacity to produce 21 different NMPA-approved medicines, 14 NMPA-approved health supplement products and 8 hemp derivative products in soft capsule, hard capsule, tablet, granule, oral liquid forms. These products address the needs of some key sectors in China, including the feminine, geriatric, and children’s markets.
Follow-Up Questions
China Health Industries Holdings Inc의 CEO는 누구입니까?
Mr. Xin Sun은 2007부터 회사에 합류한 China Health Industries Holdings Inc의 Chairman of the Board입니다.
CHHE 주식의 가격 성능은 어떻습니까?
CHHE의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
China Health Industries Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
China Health Industries Holdings Inc은 Consumer products 업종에 속하며, 해당 부문은 Consumer Staples입니다
China Health Industries Holdings Inc의 시가총액은 얼마입니까?
China Health Industries Holdings Inc의 현재 시가총액은 $0입니다
